Evelo Biosciences
Clinical stage biotech company developing a new modality of oral biologics that act on cells in the small intestine.
Clinical stage biotech company developing a new modality of oral biologics that act on cells in the small intestine.
Evelo Biosciences is a clinical stage biotechnology company that focuses on developing a new modality of oral biologics targeting the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company's first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential pharmacological properties, with the potential to offer effective, safe, and affordable medicines for inflammatory diseases and cancer.
Founded in 2015 and headquartered in the United States, Evelo Biosciences is currently advancing four product candidates in development: EDP1815, EDP1867, EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer. Moreover, the company is progressing additional product candidates in other disease areas.
With its groundbreaking approach to oral biologics and its potential to offer innovative treatments across multiple disease areas, Evelo Biosciences has garnered significant investor interest. The company recently secured a substantial $25.50M post-IPO equity investment on July 10, 2023.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $25.50M | - | 10 Jul 2023 | |
| Post-IPO Debt | $45.00M | 1 |
|
16 Dec 2022 |
| Post-IPO Equity | $67.50M | - | 29 Jan 2021 | |
| Post-IPO Debt | $45.00M | 1 |
|
25 Jul 2019 |
| Venture Round | $47.50M | 1 |
|
30 Apr 2018 |
No recent news or press coverage available for Evelo Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
